Skip to search form
Skip to main content
Skip to account menu
Semantic Scholar
Semantic Scholar's Logo
Search 205,717,413 papers from all fields of science
Search
Sign In
Create Free Account
MACOP-B regimen
Known as:
Methotrexate-Adriamycin-Cytoxan-Oncovin-Prednisone-Bleomycin Regimen
A regimen consisting of methotrexate, bleomycin, doxorubicin, cyclophosphamide, vincristine and prednisone, used to treat aggressive forms of non…
Expand
National Institutes of Health
Create Alert
Alert
Related topics
Related topics
11 relations
Broader (6)
Antineoplastic Combined Chemotherapy Protocols
Bleomycin
Cyclophosphamide
Methotrexate
Expand
Doxorubicin
Leucovorin Calcium
Lymphoma, Non-Hodgkin
Prednisone
Expand
Papers overview
Semantic Scholar uses AI to extract papers important to this topic.
Highly Cited
2004
Highly Cited
2004
Primary mediastinal large B-cell lymphoma (PMLBCL): long-term results from a retrospective multicentre Italian experience in 138 patients treated with CHOP or MACOP-B/VACOP-B
G. Todeschini
,
S. Secchi
,
+21 authors
G. Pizzolo
British Journal of Cancer
2004
Corpus ID: 1448434
The optimal treatment of primary mediastinal large B-cell lymphoma (PMLBCL) is still undefined. In the absence of randomised…
Expand
Highly Cited
2004
Highly Cited
2004
Predictive role of positron emission tomography (PET) in the outcome of lymphoma patients
P. Zinzani
,
S. Fanti
,
+12 authors
M. Baccarani
British Journal of Cancer
2004
Corpus ID: 1565845
An extensive analysis of the reliability of positron emission tomography (PET) after induction treatment in patients with Hodgkin…
Expand
Review
2004
Review
2004
Anthracycline-based chemotherapy as primary treatment for intravascular lymphoma.
A. Ferreri
,
E. Campo
,
+24 authors
M. Ponzoni
Annals of oncology : official journal of the…
2004
Corpus ID: 6758369
BACKGROUND Optimal therapeutic management of intravascular lymphoma (IVL) lacks precise guidelines. PATIENTS AND METHODS The…
Expand
Highly Cited
1999
Highly Cited
1999
Treatment and clinical management of primary mediastinal large B-cell lymphoma with sclerosis: MACOP-B regimen and mediastinal radiotherapy monitored by (67)Gallium scan in 50 patients.
P. Zinzani
,
M. Martelli
,
+10 authors
S. Tura
Blood
1999
Corpus ID: 11761141
To evaluate the efficacy of a combined modality treatment (MACOP-B plus mediastinal radiotherapy) and the advantages of Gallium…
Expand
Highly Cited
1997
Highly Cited
1997
High-dose chemotherapy and autologous bone marrow transplantation compared with MACOP-B in aggressive B-cell lymphoma.
A. Gianni
,
M. Bregni
,
+9 authors
G. Bonadonna
The New England journal of medicine
1997
Corpus ID: 2415184
BACKGROUND We compared a regimen of six chemotherapeutic agents administered sequentially at high doses, followed by…
Expand
Highly Cited
1993
Highly Cited
1993
Comparison of a standard regimen (CHOP) with three intensive chemotherapy regimens for advanced non-Hodgkin's lymphoma.
R. Fisher
,
E. Gaynor
,
+6 authors
T. Miller
The New England journal of medicine
1993
Corpus ID: 45482792
BACKGROUND CHOP is a first-generation, combination-chemotherapy regimen consisting of cyclophosphamide, doxorubicin, vincristine…
Expand
Highly Cited
1993
Highly Cited
1993
Primary mediastinal B-cell lymphoma with sclerosis: an aggressive tumor with distinctive clinical and pathologic features.
M. Lazzarino
,
E. Orlandi
,
+7 authors
M. C. Buonanno
Journal of clinical oncology : official journal…
1993
Corpus ID: 7973853
PURPOSE To evaluate the clinical features of presentation, the morphologic and immunohistochemical pattern, the modality of…
Expand
Highly Cited
1992
Highly Cited
1992
MACOP-B treatment in diffuse large-cell lymphoma: identification of prognostic groups in an Italian multicenter study.
U. Vitolo
,
M. Bertini
,
+7 authors
V. Meneghini
Journal of clinical oncology : official journal…
1992
Corpus ID: 20443515
PURPOSE The prognosis of advanced-stage diffuse large-cell lymphoma (DLCL) has improved with the use of the third-generation…
Expand
Highly Cited
1990
Highly Cited
1990
Prognostic significance of actual dose intensity in diffuse large-cell lymphoma: results of a tree-structured survival analysis.
L. Kwak
,
J. Halpern
,
R. Olshen
,
S. Horning
Journal of clinical oncology : official journal…
1990
Corpus ID: 13501066
While diffuse large-cell lymphoma (DLCL) is considered to be highly curable with current therapy, treatment failures are observed…
Expand
Highly Cited
1985
Highly Cited
1985
MACOP-B chemotherapy for the treatment of diffuse large-cell lymphoma.
P. Klimo
,
J. Connors
Annals of internal medicine
1985
Corpus ID: 41888421
Between April 1981 and May 1984, 61 patients with advanced diffuse large-cell lymphoma completed treatment with MACOP-B…
Expand
By clicking accept or continuing to use the site, you agree to the terms outlined in our
Privacy Policy
,
Terms of Service
, and
Dataset License
ACCEPT & CONTINUE